Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'fibrates' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 74 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Robins, SJ
      PPAR alpha ligands and clinical trials: cardiovascular risk reduction withfibrates

      JOURNAL OF CARDIOVASCULAR RISK
    2. Shek, A; Ferrill, MJ
      Statin-fibrate combination therapy

      ANNALS OF PHARMACOTHERAPY
    3. Gaist, D; Rodriguez, LAG; Huerta, C; Hallas, J; Sindrup, SH
      Lipid-lowering drugs and risk of myopathy: A population based follow-up study

      EPIDEMIOLOGY
    4. Steinmetz, A; Fenselau, S; Schrezenmeir, J
      Treatment of dyslipoproteinemia in the metabolic syndrome

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    5. Okopien, B; Cwalina, L; Lebek, M; Kowalski, J; Zielinski, M; Wisniewska-Wanat, M; Kalina, Z; Herman, ZS
      Effects of fibrates on plasma prothrombotic activity in patients with TypeIIb dyslipidemia

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    6. Nordt, TK; Lutzi, S; Ruef, J; Peter, K; Klar, E; Kubler, W; Sobel, BE; Bode, C
      Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells

      THROMBOSIS AND HAEMOSTASIS
    7. Lipscombe, J; Lewis, GF; Cattran, D; Bargman, JM
      Deterioration in renal function associated with fibrate therapy

      CLINICAL NEPHROLOGY
    8. Minnich, A; Tian, N; Byan, L; Bilder, G
      A potent PPAR alpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle

      AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    9. Caroli-Bosc, FX; Le Gall, P; Pugliese, P; Delabre, B; Caroli-Bosc, C; Demarquary, JF; Delmont, JP; Rampal, P; Montet, JC
      Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation epidemiological - Study in an unselected population

      DIGESTIVE DISEASES AND SCIENCES
    10. Umeda, Y; Kako, Y; Mizutani, K; Iikura, Y; Kawamura, M; Seishima, M; Hayashi, H
      Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine

      JOURNAL OF LIPID RESEARCH
    11. Bae, JH; Bassenge, E; Lee, HJ; Park, KR; Park, CG; Park, KY; Lee, MS; Schwemmer, M
      Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates

      ATHEROSCLEROSIS
    12. Karpe, F; Taskinen, MR; Nieminen, MS; Frick, MH; Kesaniemi, YA; Pasternack, A; Hamsten, A; Syvanne, M
      Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment

      ATHEROSCLEROSIS
    13. Neve, BP; Corseaux, D; Chinetti, G; Zawadzki, C; Fruchart, JC; Duriez, P; Staels, B; Jude, B
      PPAR alpha agonists inhibit tissue factor expression in human monocytes and macrophages

      CIRCULATION
    14. Hertz, R; Sheena, V; Kalderon, B; Berman, I; Bar-Tana, J
      Suppression of hepatocyte nuclear factor-4 alpha by acyl-CoA thioesters ofhypolipidemic peroxisome proliferators

      BIOCHEMICAL PHARMACOLOGY
    15. Rodriguez, C; Cabrero, A; Roglans, N; Adzet, T; Sanchez, RM; Vazquez, M; Ciudad, CJ; Laguna, JC
      Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells

      BIOCHEMICAL PHARMACOLOGY
    16. Gervois, P; Torra, IP; Fruchart, JC; Staels, B
      Regulation of lipid and lipoprotein metabolism by PPAR activators

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    17. Van Veldhoven, PP; Mannaerts, GP; Declercq, P; Baes, M
      Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?

      CELLULAR SIGNALLING
    18. Milionis, HJ; Elisaf, MS; Mikhailidis, DP
      Treatment of dyslipidaemias in patients with established vascular disease:A revival of the fibrates

      CURRENT MEDICAL RESEARCH AND OPINION
    19. Nilsson, L; Takemura, T; Eriksson, P; Hamsten, A
      Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    20. Clavey, V; Copin, C; Mariotte, MC; Bauge, E; Chinetti, G; Fruchart, J; Fruchart, JC; Dallongeville, J; Staels, B
      Gels culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells

      CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
    21. Orth, M; Mayer, H; Halle, M; Luley, C
      Hemostatic factors in hypertriglyceridemic men: Effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate

      THROMBOSIS RESEARCH
    22. Ribalta, J; Girona, J; Vallve, JC; La Ville, AE; Heras, M; Masana, L
      Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia

      JOURNAL OF LIPID RESEARCH
    23. Pritzker, LB
      Do lipid lowering drugs reduce the risk of coronary heart disease?

      CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
    24. MADEJ A; OKOPIEN B; KOWALSKI J; ZIELINSKI M; WYSOCKI J; SZYGULA B; KALINA Z; HERMAN ZS
      EFFECTS OF FENOFIBRATE ON PLASMA CYTOKINE CONCENTRATIONS IN PATIENTS WITH ATHEROSCLEROSIS AND HYPERLIPOPROTEINEMIA IIB

      International journal of clinical pharmacology and therapeutics
    25. GLORIAN M; FRANCKHAUSERVOGEL S; ROBIN D; ROBIN P; FOREST C
      GLUCOCORTICOIDS REPRESS INDUCTION BY THIAZOLIDINEDIONES, FIBRATES, AND FATTY-ACIDS OF PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE-EXPRESSION IN ADIPOCYTES

      Journal of cellular biochemistry
    26. GANNECARRIE N; DELEUSSE A; GUETTIER C; CASTERA L; LEVECQ H; BERTRAND HJ; PLUMET Y; TRINCHET JC; BEAUGRAND M
      AUTOIMMUNE HEPATITIS ASSOCIATED WITH FIBRATE TREATMENT

      Gastroenterologie clinique et biologique
    27. EDGAR AD; TOMKIEWICZ C; COSTET P; LEGENDRE C; AGGERBECK M; BOUGUET J; STAELS B; GUYOMARD C; PINEAU T; BAROUKI R
      FENOFIBRATE MODIFIES TRANSAMINASE GENE-EXPRESSION VIA A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA-DEPENDENT PATHWAY

      Toxicology letters
    28. BHATNAGAR D
      LIPID-LOWERING DRUGS IN THE MANAGEMENT OF HYPERLIPIDEMIA

      Pharmacology & therapeutics (Oxford)
    29. BISGAIER CL; ESSENBURG AD; BARNETT BC; AUERBACH BJ; HAUBENWALLNER S; LEFF T; WHITE AD; CREGER P; PAPE ME; REA TJ; NEWTON RS
      A NOVEL COMPOUND THAT ELEVATES HIGH-DENSITY-LIPOPROTEIN AND ACTIVATESTHE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR

      Journal of lipid research
    30. DARIMONT C; GRADOUX N; CUMIN F; BAUM HP; DEPOVER A
      DIFFERENTIAL REGULATION OF INTESTINAL AND LIVER FATTY-ACID-BINDING PROTEINS IN HUMAN INTESTINAL-CELL LINE (CACO-2) - ROLE OF COLLAGEN

      Experimental cell research
    31. STAELS B; DALLONGEVILLE J; AUWERX J; SCHOONJANS K; LEITERSDORF E; FRUCHART JG
      MECHANISM OF ACTION OF FIBRATES ON LIPID AND LIPOPROTEIN METABOLISM

      Circulation
    32. NEELE DM; KAPTEIN A; HUISMAN H; DEWIT ECM; PRINCEN HMG
      NO EFFECT OF FIBRATES ON SYNTHESIS OF APOLIPOPROTEIN(A) IN PRIMARY CULTURES OF CYNOMOLGUS MONKEY AND HUMAN HEPATOCYTES - APOLIPOPROTEIN-A-ISYNTHESIS INCREASED

      Biochemical and biophysical research communications
    33. Turpin, G; Bruckert, E
      Management of atherogenic hyperlipidaemia.

      ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE
    34. ARTS J; KOCKX M; PRINCEN HMG; KOOISTRA T
      STUDIES ON THE MECHANISM OF FIBRATE-INHIBITED EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN CULTURED-HEPATOCYTES FROM CYNOMOLGUS MONKEY

      Arteriosclerosis, thrombosis, and vascular biology
    35. PERREAULT S; HAMILTON VH; LAVOIE F; GROVER S
      A HEAD-TO-HEAD COMPARISON OF THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS AND FIBRATES IN DIFFERENT TYPES OF PRIMARY HYPERLIPIDEMIA

      Cardiovascular drugs and therapy
    36. MULS E; VANGAAL L; AUTIER P; VANSANT G
      EFFECTS OF INITIAL BMI AND ON-TREATMENT WEIGHT CHANGE ON THE LIPID-LOWERING EFFICACY OF FIBRATES

      International journal of obesity
    37. SCOTT R
      LIPID MODIFYING AGENTS - MECHANISMS OF ACTION AND REDUCTION OF CARDIOVASCULAR-DISEASE

      Clinical and experimental pharmacology and physiology
    38. FRANCKHAUSERVOGEL S; GLORIAN M; FOREST C
      GLUCOCORTICOIDS USE A POSITIVE LIVER ELEMENT TO REPRESS FIBRATE-INDUCED ADIPOSE TRANSCRIPTION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE

      Molecular and cellular endocrinology
    39. HANDLEY DA; HUGHES TE
      PHARMACOLOGICAL APPROACHES AND STRATEGIES FOR THERAPEUTIC MODULATION OF FIBRINOGEN

      Thrombosis research
    40. FROYLAND L; MADSEN L; VAAGENES H; TOTLAND GK; AUWERX J; KRYVI H; STAELS B; BERGE RK
      MITOCHONDRION IS THE PRINCIPAL TARGET FOR NUTRITIONAL AND PHARMACOLOGICAL CONTROL OF TRIGLYCERIDE-METABOLISM

      Journal of lipid research
    41. HAWKE RL; CHAPMAN JM; WINEGAR DA; SALISBURY JA; WELCH RM; BROWN A; FRANZMANN KW; SIGEL C
      POTENT HYPOCHOLESTEROLEMIC ACTIVITY OF NOVEL UREIDO PHENOXYISOBUTYRATES CORRELATES WITH THEIR INTRINSIC FIBRATE POTENCY AND NOT WITH THEIR ACAT INHIBITORY ACTIVITY

      Journal of lipid research
    42. HAVEL RJ
      BENEFITS OF FIBRATE DRUGS IN CORONARY HEART-DISEASE PATIENTS WITH NORMAL CHOLESTEROL LEVELS

      Circulation
    43. SABORDO L; SALLUSTIO BC
      EFFECTS OF GEMFIBROZIL AND CLOFIBRIC ACID ON THE UPTAKE OF TAUROCHOLATE BY ISOLATED RAT HEPATOCYTES

      Biochemical pharmacology
    44. GANOTAKIS ES; JAGROOP IA; HAMILTON G; WINDER AF; MIKHAILIDIS DP
      PRELIMINARY-REPORT - CIPROFIBRATE-FLUVASTATIN COMBINATION THERAPY FORDYSLIPIDEMIA

      Journal of drug development and clinical practice
    45. DEPINIEUX G; CHARIOT P; AMMISAID M; LOUARN F; LEJONC JL; ASTIER A; JACOTOT B; GHERARDI R
      LIPID-LOWERING DRUGS AND MITOCHONDRIAL-FUNCTION - EFFECTS OF HMG-COA REDUCTASE INHIBITORS ON SERUM UBIQUINONE AND BLOOD LACTATE PYRUVATE RATIO/

      British journal of clinical pharmacology
    46. PACKARD CJ
      LDL SUBFRACTIONS AND ATHEROGENICITY - AN HYPOTHESIS FROM THE UNIVERSITY-OF-GLASGOW

      Current medical research and opinion
    47. JONES PH; POWNALL HJ; PATSCH W; HERD JA; FARMER JA; PAYTONROSS C; KIMBALL KT; GOTTO AM; MORRISETT JD
      EFFECT OF GEMFIBROZIL ON LEVELS OF LIPOPROTEIN[A] IN TYPE-II HYPERLIPOPROTEINEMIC SUBJECTS

      Journal of lipid research
    48. KRAUSE BR; BARNETT BC; ESSENBURG AD; KIEFT KA; AUERBACH BJ; BOUSLEY R; STANFIELD R; NEWTON RS; BISGAIER CL
      OPPOSITE EFFECTS OF BEZAFIBRATE AND GEMFIBROZIL IN BOTH NORMAL AND HYPERTRIGLYCERIDEMIC RATS

      Atherosclerosis
    49. AUWERX J; SCHOONJANS K; FRUCHART JC; STAELS B
      TRANSCRIPTIONAL CONTROL OF TRIGLYCERIDE-METABOLISM - FIBRATES AND FATTY-ACIDS CHANGE THE EXPRESSION OF THE LPL AND APO C-III GENES BY ACTIVATING THE NUCLEAR RECEPTOR PPAR

      Atherosclerosis
    50. SCATENA R; NOCCA G; MESSANA I; DESOLE P; BARONI S; ZUPPI C; CASTAGNOLA M; GIARDINA B
      EFFECTS OF GEMFIBROZIL ON THE OXYGEN-TRANSPORT PROPERTIES OF ERYTHROCYTES

      British journal of clinical pharmacology
    51. KOENIG W
      RECENT PROGRESS IN THE CLINICAL ASPECTS OF FIBRINOGEN

      European heart journal
    52. MURPHY MJ; DUNCAN A; VALLANCE BD; PACKARD CJ; OREILLY DS
      IATROGENIC PROFOUND HYPOALPHALIPOPROTEINEMIA - AN UNRECOGNIZED CAUSE OF VERY-LOW HDL CHOLESTEROL

      Postgraduate medical journal
    53. KINSCHERF R; METZ J; WULFROTH P
      ETOFIBRATE SUPPRESSES NEOINTIMA FORMATION OF THE BALLOONED COMMON CAROTID-ARTERY OF RATS

      Naunyn-Schmiedeberg's archives of pharmacology
    54. FRANCESCHINI G; LOVATI MR; MANZONI C; MICHELAGNOLI S; PAZZUCCONI F; GIANFRANCESCHI G; VECCHIO G; SIRTORI CR
      EFFECT OF GEMFIBROZIL TREATMENT IN HYPERCHOLESTEROLEMIA ON LOW-DENSITY-LIPOPROTEIN (LDL) SUBCLASS DISTRIBUTION AND LDL-CELL INTERACTION

      Atherosclerosis
    55. ANTRASFERRY J; ROBIN P; ROBIN D; FOREST C
      FATTY-ACIDS AND FIBRATES ARE POTENT INDUCERS OF TRANSCRIPTION OF THE PHOSPHENOLPYRUVATE CARBOXYKINASE GENE IN ADIPOCYTES

      European journal of biochemistry
    56. BERTHOU L; SALADIN R; YAQOOB P; BRANELLEC D; CALDER P; FLUCHART JC; DENEFLE P; AUWERX J; STAELS B
      REGULATION OF RAT-LIVER APOLIPOPROTEIN-A-I, APOLIPOPROTEIN-A-II AND ACYL-COENZYME-A OXIDASE GENE-EXPRESSION BY FIBRATES AND DIETARY FATTY-ACIDS

      European journal of biochemistry
    57. VAZQUEZ M; ALEGRET M; LOPEZ MC; RODRIGUEZ C; ADZET T; MERLOS M; LAGUNA JC
      DIFFERENT EFFECTS OF FIBRATES ON THE MICROSOMAL FATTY-ACID CHAIN ELONGATION AND THE ACYL COMPOSITION OF PHOSPHOLIPIDS IN GUINEA-PIGS

      British Journal of Pharmacology
    58. VAZQUEZ M; MUNOZ S; ALEGRET M; ADZET T; MERLOS M; LAGUNA JC
      DIFFERENTIAL-EFFECTS OF FIBRATES ON THE ACYL COMPOSITION OF MICROSOMAL PHOSPHOLIPIDS IN RATS

      British Journal of Pharmacology
    59. ALEGRET M; CERQUEDA E; FERRANDO R; VAZQUEZ M; SANCHEZ RM; ADZET T; MERLOS M; LAGUNA JC
      SELECTIVE MODIFICATION OF RAT HEPATIC-MICROSOMAL FATTY-ACID CHAIN ELONGATION AND DESATURATION BY FIBRATES - RELATIONSHIP WITH PEROXISOME PROLIFERATION

      British Journal of Pharmacology
    60. KRAUSE BR; BOUSLEY R; KIEFT K; ROBERTSON D; STANFIELD R; URDA E; NEWTON RS
      COMPARISON OF LIFIBROL TO OTHER LIPID-REGULATING AGENTS IN EXPERIMENTAL-ANIMALS

      Pharmacological research
    61. KNIPSCHEER HC; NURMOHAMED MT; VANDENENDE A; PLAAT B; PRUIJS HJW; MULDER WJ; KASTELEIN JJP
      GEMFIBROZIL TREATMENT OF THE HIGH TRIGLYCERIDE-LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL TRAIT IN MEN WITH ESTABLISHED ATHEROSCLEROSIS

      Journal of internal medicine
    62. FOGER B; DREXEL H; HOPFERWIESER T; MIESENBOCK G; RITSCH A; LECHLEITNER M; TROBINGER G; PATSCH JR
      FENOFIBRATE IMPROVES POSTPRANDIAL CHYLOMICRON CLEARANCE IN IIB-HYPERLIPOPROTEINEMIA

      The Clinical investigator
    63. MAGGI FM; PIGLIONICA MR; DEMICHELE L; BARONI S; BIASI GM; CATAPANO AL
      BEZAFIBRATE LOWERS ELEVATED PLASMA-LEVELS OF FIBRINOGEN AND LIPOPROTEIN(A) IN PATIENTS WITH TYPE-IIA AND TYPE-B DYSLIPOPROTEINEMIA

      NMCD. Nutrition Metabolism and Cardiovascular Diseases
    64. BOUMENDIL EF
      DESCRIPTIVE STUDY OF LIPID-MODULATING DRUG-USE IN A FRENCH PROFESSIONAL POPULATION

      Journal of clinical epidemiology
    65. LEPICARD A; MALLAT A; ZAFRANI ES; DHUMEAUX D
      CHRONIC INJURY OF INTERLOBULAR BILE-DUCTS INDUCED BY FENOFIBRATE

      Gastroenterologie clinique et biologique
    66. LOZADA A; DUJOVNE CA
      DRUG-INTERACTIONS WITH FIBRIC ACIDS

      Pharmacology & therapeutics
    67. JACOBSON TA
      COMBINATION-DRUG THERAPY FOR HYPERLIPIDEMIA

      Clinical cardiology
    68. SCHONFELD G
      THE EFFECTS OF FIBRATES ON LIPOPROTEIN AND HEMOSTATIC CORONARY RISK-FACTORS

      Atherosclerosis
    69. SHEPHERD J
      THE FIBRATES IN CLINICAL-PRACTICE - FOCUS ON MICRONIZED FENOFIBRATE

      Atherosclerosis
    70. GAW A; PACKARD CJ; CASLAKE MJ; GRIFFIN BA; LINDSAY GM; THOMSON J; VALLANCE BD; WOSORNU D; SHEPHERD J
      EFFECTS OF CIPROFIBRATE ON LDL METABOLISM IN MAN

      Atherosclerosis
    71. STEIN EA
      DRUG AND ALTERNATIVE THERAPIES FOR HYPERLIPIDEMIA

      Atherosclerosis
    72. ALEGRET M; FERRANDO R; VAZQUEZ M; ADZET T; MERLOS M; LAGUNA JC
      RELATIONSHIP BETWEEN PLASMA-LIPIDS AND PALMITOYL-COA HYDROLASE AND SYNTHETASE ACTIVITIES WITH PEROXISOMAL PROLIFERATION IN RATS TREATED WITH FIBRATES

      British Journal of Pharmacology
    73. FRANCESCHINI G; PAOLETTI R
      PHARMACOLOGICAL CONTROL OF HYPERTRIGLYCERIDEMIA

      Cardiovascular drugs and therapy
    74. FUHRER JA; MONTANDON A; DESCOEUDRES C; JAEGER P; HORBER FF
      IMPACT OF TIME-INTERVAL AFTER TRANSPLANTATION AND THERAPY WITH FIBRATES ON SERUM-CHOLESTEROL LEVELS IN RENAL-TRANSPLANT PATIENTS

      Clinical nephrology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/06/20 alle ore 11:33:53